Pulmonary embolism is one of the most lethal complications facing cancer patients, and diagnosing it has long required computed tomographic pulmonary angiography (CTPA) — an imaging modality that carries its own risks in this already vulnerable population, including radiation exposure, contrast-induced nephropathy, and logistical burden. A validated clinical decision tool that could safely reduce unnecessary imaging would represent a meaningful advance in oncologic care.
This randomized noninferiority trial, published in JAMA, evaluated whether the YEARS algorithm — a three-item clinical decision rule assessing DVT signs, hemoptysis, and whether PE is the most likely diagnosis — could safely triage cancer patients with suspected PE without universal CTPA. The YEARS framework stratifies patients by clinical probability and D-dimer thresholds to determine who truly requires imaging. The trial tested whether this approach was non-inferior to standard CTPA-first practice in terms of missed PE events (the primary safety endpoint) while also measuring the proportion of scans avoided (efficiency endpoint) in a population of patients with active malignancy.
This finding matters for several reasons beyond simple diagnostic convenience. Cancer patients are disproportionately harmed by over-imaging: contrast nephropathy interacts badly with chemotherapy nephrotoxicity, cumulative radiation is a real concern in long-term survivors, and healthcare resource consumption is already enormous in oncology settings. The YEARS algorithm has been validated in the general population and in pregnancy, but cancer patients present a distinctly high-pretest-probability group where clinical decision rules have historically performed less reliably. If confirmed, extending YEARS to this cohort would challenge the default assumption that cancer automatically mandates direct imaging. The key limitations to weigh: cancer heterogeneity (solid vs. hematologic, metastatic vs. localized) may dilute subgroup safety signals, and noninferiority margins in PE trials remain contested. This trial, however, represents high-quality evidence from a meaningful clinical setting.